On their family farm in rural Illinois, the Flessner boys have free range. But early on, something was holding older brother ...

Duchenne muscular dystrophy (DMD) is one of the most common and devastating childhood genetic disorders, affecting ...

A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle ...

The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin ...

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and ...

Columnist Shalom Lim appreciates how Duchenne never offers a dull moment as he prepares for the challenges and adventures in ...

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National ...

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision ...

UK MHRA grants conditional marketing authorisation to Italfarmaco’s givinostat to treat patients with Duchenne muscular dystrophy: United Kingdom Tuesday, December 24, 2024, 12: ...

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) inpatients aged 4 years and older Follows recent approval from China’s National ...

In the pivotal VISION-DMD study, AGAMREE met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability ...